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Abstract
Background:  Prostate inflammation or infection may increase the risk of prostate cancer.
Antibiotics and non-steroidal anti-inflammatory drugs (NSAIDs) are used to treat prostatitis and
urinary tract infections (UTIs). The objective of our study was to assess whether their use
decreases the risk of prostate cancer.
Methods: We conducted a case-control study among men with incident prostate cancer (N = 65
cases) and without prostate cancer (N = 195 controls) at the San Francisco Veteran Affairs medical
center (VAMC) between June 1996 and June 2006. Cases were all patients who had prostate
biopsies positive for cancer. We matched controls to cases on age group and race at a 3:1 ratio,
and each matched pair was given an identical index date. Total antibiotic, aspirin, and NSAID use
(number of prescriptions) was computed for each participant by drug type and was restricted to a
fill date at least 1 year before the index date. Logistic regression was used for analysis. We adjusted
for the matching variables (age group and race) and potential confounders (years of VAMC
enrollment and number of clinic visits).
Results: Neither total antibiotic use nor total anti-inflammatory use reduces the risk of prostate
cancer (P > 0.05).
Conclusion: Our analysis did not reveal a relation between use of antibiotics, aspirin, or NSAIDs
and the risk of prostate cancer.
Background
Prostate cancer is a major cause of morbidity and mortal-
ity in the United States and worldwide. Age, race, and fam-
ily history are known risk factors for prostate cancer, but
there is also limited biological and epidemiological evi-
dence that suggest prostate inflammation or infection,
also known as prostatitis, may increase the risk of prostate
cancer [1,2]. Antibiotics and non-steroidal anti-inflam-
matory drugs (NSAIDs) are often used to treat prostatitis
and urinary tract infections (UTIs) in men. Although pros-
tatitis may be present in patients diagnosed with prostate
cancer, the prevalence and incidence of prostatitis are
thought to exceed that of prostate cancer [1-6].
Our hypothesis is that antibiotic use and/or use of
NSAIDs may decrease the risk of prostate cancer. There is
strong and consistent evidence from animal and labora-
tory studies, which suggest that regular use of NSAIDs may
reduce prostate cancer risk [7-9]. Previous studies also
indicate that NSAIDs have an inhibitory effect on prostate
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cancer cells, which suggests that prostaglandins play a piv-
otal role in prostate cancer biology [10-15]. Although
cyclooxygenase-mediated production of prostaglandins
appears to play an important role in the biology of pros-
tate cancer, NSAIDs may have several mechanisms of
action against prostate cancer, including apoptosis, inhi-
bition of angiogenesis and cellular growth [16,7-9].
Chemoprevention of prostate cancer, which is the primary
focus of our study, evaluates drugs which may reduce the
risk of prostate cancer with the goal of reducing the inci-
dence of prostate cancer, as well as reducing treatment-
related morbidity [17]. Our study examines whether
known treatment for prostatitis, such as antibiotics and
anti-inflammatory drugs, decreases the risk of subsequent
prostate cancer. This is the first study to evaluate the effect
of antibiotics on prostate cancer risk.
Methods
To investigate our hypothesis that antibiotics, aspirin, and
NSAIDs (refers only to non-aspirin, nonselective NSAIDs)
decrease the risk of incident prostate cancer, we conducted
a case-control study of patients diagnosed with prostate
cancer and compared them to general internal medicine
clinic-based controls without known prostate cancer, fre-
quency-matched to cases on age and race/ethnicity. Our
study design is similar to studies performed evaluating the
association between antibiotics and breast cancer [18-20].
We used computerized medical record information from
the San Francisco VAMC. Patients eligible for the study
were men enrolled at SF Veterans Administration Medical
Center (VAMC) system before July 1, 2000 and were at
least 40 years of age or older at the time of VAMC enroll-
ment. In addition, patients had to have at least one pros-
tate specific antigen (PSA) test in the past 10 years
(between June 1996 and June 2006) and must have been
seen in a General Medicine Practice Clinic on two or more
occasions between June 1996 and June 2006. The study
protocol was approved by the Committee on Human
Research of the University of California, San Francisco.
Variables extracted included race and ethnicity, prostate
biopsy results, prostate cancer diagnosis, history of acute
or chronic prostatitis; number of health care visits, history
of UTIs (clinically diagnosed or urine testing with white
blood cell count of >10), history of benign prostatic
hyperplasia (BPH). The pharmacy database was used to
determine the amount and duration of antimicrobial and
non-steroidal anti-inflammatory use (including the
cumulative number of days of medication use and the
total number of prescriptions) for the following medica-
tions: antibiotics (macrolides, azithromycin, erythromy-
cin, clarithromycin, tetracyclines, doxycycline, penicillins,
cephelexin, cephalosporins, sulfonamides, TMP-SMX,
ciprofloxacin, levofloxacin), antivirals, antifungals, anti-
inflammatory medications (non-steroidal anti-inflamma-
tory medication, COX-2 inhibitors, aspirin, anti-TNF
medications), and other medications of interest (testoster-
one, finasteride, alpha receptor blockers).
We identified 65 patients with a recorded biopsy-positive
prostate cancer. We conducted a case-control study
among men with incident prostate cancer (N = 65 cases)
and without prostate cancer (N = 195 controls) at the SF
VAMC between June 1996 and June 2006. Cases were all
patients who had prostate biopsies positive for cancer.
The prostate cancer diagnosis date was designated as the
index date. We randomly matched controls to cases on age
group and race at a 3:1 ratio, and each matched pair was
given an identical index date. Total antibiotic (anti-bacte-
rial agents only), antimicrobial use (antibacterial, antivi-
rals, and antifungals combined) and NSAIDs, or aspirin
use (number of prescriptions) was computed for each par-
ticipant by drug type and was restricted to a fill date at
least 1 year before the index date. Logistic regression was
used for analysis. We adjusted for the matching variables
(age group and race, which are well-accepted risk factors
for prostate cancer) as well as for potential confounders
(years of VAMC enrollment and number of clinic visits)
which increase the likelihood of having a prostate cancer
diagnosis. We used STATA 9.2 (STATCORP, College Sta-
tion, TX) for statistical analysis. A multiple logistic regres-
sion model was used to model the overall association of
antibiotics, antimicrobials, NSAIDs, aspirin use and mul-
tiple covariates and was used to calculate the odds ratios
(ORs) and 95% confidence intervals (CIs). Quantity of
medication use was grouped into five categories according
to increasing number of prescriptions prescribed.
Results
Demographic and some health characteristics for the VA
sample are reported in Table 1. In our analysis, 65 case-
patients and 195 control-patients were included in our
analysis. Median age of case-patients was 78 years (range:
51–99 years) vs. 77 years (range: 52–96 years) for control-
patients. The majority of study participants were White
(43%) or Black (26%). Although not statistically signifi-
cant, case-patients (87%) were more likely than control-
patients (77%), to have a history of UTI (P = .08). Case-
patients had a greater number of clinic visits (mean 146)
compared to control-patients (mean 123) P = 0.01. There
were 14 (7%) control-patients who had finasteride use,
with an average of 398.6 doses per individual. None of the
prostate cancer patients had prior finasteride use.
In a multiple logistic regression model (Table 2), after
adjustment for the matching variables (age group and
race), as well as the potential confounders (number of
UTIs, years of enrollment, and number of visits), total
antibiotic use, antimicrobial use, anti-inflammatory use,BMC Research Notes 2009, 2:57 http://www.biomedcentral.com/1756-0500/2/57
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or aspirin use did not reduce the risk of incident prostate
cancer. A higher levels of antibiotic, NSAIDs, and aspirin
use was also not associated with a reduced risk of prostate
cancer (tests for trend, p = 0.33, 0.23, and 0.35, respec-
tively). Subgroup analysis for specific classes of antibiotics
(cephalosporins, macrolides, penicillins, quinolones, sul-
fonamides, and tetracyclines) also did not reveal any sig-
nificant effect on prostate cancer risk (data not shown).
Discussion
Our analysis did not reveal an association between the use
of antibiotics, NSAIDs, or aspirin and the risk of prostate
cancer. Our study is the first report to assess the relation-
ship between prostate cancer and antibiotics. It is plausi-
ble that some classes of antibiotics may have an effect on
prostate cancer by reducing prostate infections and
inflammatory responses. Both microbiological and epide-
miologic studies show that microbes that commonly
infect or inflame the prostate may be associated with pros-
tate cancer [21-28]. To further clarify whether antimicro-
bial agents influence prostate cancer, studies in a larger
sample, given our wide confidence intervals, should be
strongly considered to definitively answer this research
question. For example, the confidence interval examining
the effect of antibiotics (0.30 to 1.98) includes a potential
70% reduction in the odds of prostate cancer among the
highest users of antibiotics.
Previous epidemiological studies have assessed the associ-
ation of NSAIDs with prostate cancer. Studies have found
that NSAIDs or aspirin may reduce the risk of prostate
cancer; differences have been found between NSAIDs and
aspirin use and prostate cancer risk, [10-13] so our evalu-
ation also analyzed these classes of medications sepa-
rately. In a cross-sectional, self-administered survey of
over 1200 Canadian men, aspirin use was associated with
a 42% reduction in the odds of prostate cancer, but
NSAIDs were not related to prostate cancer risk [12]. In a
longitudinal study of predominantly white men in Min-
nesota (n = 1362), age 50–79 years, NSAIDs use had a rel-
ative odds of 0.45 (95% CI 0.28–0.73) with 6 years of
follow-up [13]. Unfortunately, this study only assessed
NSAIDs use at baseline [13]. In a case-control study of
men age 65 years and older who had undergone prostate
biopsy, NSAIDs/COX-2 inhibitors or aspirin use during a
2 year period reduced the likelihood of prostate cancer
with over 2000 cases and similar number control partici-
pants with NSAIDs/COX-2 inhibitors: OR 0.71 (95% CI
058–0.86) and aspirin: OR 0.84 (95% CI 0.74–0.96) [11].
A systematic review of 12 studies (5 retrospective and 7
prospective) found a summary odds ratio for aspirin and
prostate cancer risk of 0.9 (95% CI 0.82–0.99), but reduc-
tion in risk with the use of other NSAIDs was less consist-
ent with a combined OR 0.87 (95% CI 0.61–1.23) [10].
Despite substantial evidence of a reduced incidence of
prostate cancer with NSAIDs or aspirin use, neither medi-
cation is currently prescribed as a primary chemopre-
ventative measure for prostate cancer, given potential
medication side effects and the lack of data from a rand-
omized controlled trial.
Potential limitations of our study should be recognized.
We limited our analysis to the number of pills prescribed
to patients and filled by patients. It is unknown whether
patients actually took the medications that were pre-
scribed once their prescriptions were filled. Thus, the
exposure measure may have incorrectly categorized
patients according to the number of medication expo-
sures. In addition, VA patients often see physicians out-
side of the VA system and may have obtained
Table 1: Characteristics of VA Men Cases and Controls
Cases
(n = 65)
Controls
(n = 195)
p value †
Current age
≤ 55 2 (3.1%)* 6 (3.1%) 0.98
55–65 7 (10.8%) 21 (10.8%)
65–75 17 (26.2%) 51 (26.2%)
75–85 27 (41.5%) 81 (41.5%)
85–95 11 (16.9%) 33 (16.9%)
> 95 1 (1.5%) 3 (1.5%)
Race
Asian or Pacific Islander 3 (4.6%) 9 (4.6%) 1
Black 17 (26.2%) 51 (26.2%)
Latino or Hispanic 2 (3.1%) 6 (3.1%)
White 28 (43.1%) 84 (43.1%)
Unknown 15 (23.1%) 45 (23.1%)
Number of visits
≤ 50 7 (10.8%) 44 (22.6%) 0.01
50–100 18 (27.7%) 63 (32.3%)
100–150 20 (30.8%) 48 (24.6%)
> 150 20 (30.8%) 40 (20.5%)
Years of enrollment
≤ 10 12 (18.5%) 23 (11.8%) 0.25
10–15 16 (24.6%) 55 (28.2%)
15–20 11 (16.9%) 46 (23.6%)
> 20 26 (40.0%) 71 (36.4%)
History of prostatitis 1 (1.54%) 8 (4.1%) 0.46
History of BPH 41 (63.1%) 114 (58.5%) 0.56
Elevated PSA (>4.0) 21 (32.3%) 27 (13.9%) <0.05
History of UTI 57 (87.7%) 151 (77.4%) 0.08
† The comparisons for current age, number of visits, and year of 
enrollment use the Wilcoxon rank sum test; all other comparisons 
use Fisher's exact test.
* n (%), number in parentheses are a percentage.BMC Research Notes 2009, 2:57 http://www.biomedcentral.com/1756-0500/2/57
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prescriptions outside of the VA or used over-the-counter
NSAIDs, which we could not account for in our analysis.
Another potential limitation is that our study sample
mean age was 78, which is somewhat older than the aver-
age age of 70 at time of diagnosis for prostate cancer [29].
This study was not able to assess whether antibiotics and
anti-inflammatories have a different risk in younger
patients. Future studies assessing the relationship between
antibiotic use and prostate cancer risk should consider
including only men who are at particularly high risk for
prostate cancer, such as those with high-grade prostatic
intraepithelial neoplasia (HG-PIN) on prostate biopsies
(a known precursor of prostate cancer) or those with
strong family histories or African American race, instead
of selecting all men which may mitigate detection of true
effect. Limiting the selection of patients to those who have
undergone a prostate biopsy may also reduce, but not
eliminate, the possibility of detection bias.
Conclusion
In summary, current data from the San Francisco VAMC
database does not provide evidence of support for the
hypothesis that antibiotics or NSAIDs decrease the risk of
prostate cancer.
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